Novartis announced data Monday that could set up one of the biggest marketing battles in cancer.
At issue is the market for medicines called CDK 4/6 inhibitors. The first of these drugs, Pfizer’s Ibrance, is a $5-billion-a-year product and one of that company’s top sellers. But it has been losing market share to Eli Lilly’s Verzenio.
Novartis said in a press release that its CDK 4/6, Kisqali, had succeeded in a Phase 3 trial looking at adjuvant use — that’s use after a tumor is surgically removed to prevent recurrence. Further details were not available. Novartis said more complete data would be presented at a medical meeting in the future.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect